JP2008520746A - アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療 - Google Patents

アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療 Download PDF

Info

Publication number
JP2008520746A
JP2008520746A JP2007543474A JP2007543474A JP2008520746A JP 2008520746 A JP2008520746 A JP 2008520746A JP 2007543474 A JP2007543474 A JP 2007543474A JP 2007543474 A JP2007543474 A JP 2007543474A JP 2008520746 A JP2008520746 A JP 2008520746A
Authority
JP
Japan
Prior art keywords
substituted
cancer
hif
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543474A
Other languages
English (en)
Japanese (ja)
Inventor
ピアー ボリア アンドリア
ピアー バラルディ ジョバンニ
メリーギ ステファニア
マクレナン ステファン
レオン エドワード
ムアマン アラン
Original Assignee
キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド filed Critical キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド
Publication of JP2008520746A publication Critical patent/JP2008520746A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2007543474A 2004-11-22 2005-11-22 アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療 Pending JP2008520746A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055704P 2004-11-22 2004-11-22
PCT/US2005/042551 WO2007040565A2 (fr) 2004-11-22 2005-11-22 Amelioration du traitement du cancer et de troubles medies par hif-1 au moyen d'antagonistes des recepteurs de l'adenosine a3

Publications (1)

Publication Number Publication Date
JP2008520746A true JP2008520746A (ja) 2008-06-19

Family

ID=37906593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543474A Pending JP2008520746A (ja) 2004-11-22 2005-11-22 アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療

Country Status (6)

Country Link
EP (1) EP1827445A2 (fr)
JP (1) JP2008520746A (fr)
AU (1) AU2005336924A1 (fr)
CA (1) CA2586420A1 (fr)
IL (1) IL183307A0 (fr)
WO (1) WO2007040565A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (fr) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Composes heteroaromatiques azotes pour le traitement des maladies de cancer
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
EP1797881B1 (fr) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Composition medicamenteuse avec une stabilite amelioree et une tendence de gelification reduite
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
EP2036557B1 (fr) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
BRPI0921257A2 (pt) * 2008-11-14 2016-02-23 Bayer Schering Pharma Ag composto de arila heterociclicamente subsittuidos como inibidores hif
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
WO2014153363A1 (fr) * 2013-03-18 2014-09-25 Northeastern University Procédé de génération d'anticorps anti-pathogènes généralement neutralisants
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2021028382A1 (fr) 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2022029063A1 (fr) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
WO2007040565A3 (fr) 2009-04-16
EP1827445A2 (fr) 2007-09-05
CA2586420A1 (fr) 2007-04-12
AU2005336924A1 (en) 2007-04-12
WO2007040565A2 (fr) 2007-04-12
IL183307A0 (en) 2008-04-13
WO2007040565A9 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
JP2008520746A (ja) アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療
US20240091177A1 (en) Methods for treating cancer
US20060204502A1 (en) Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
EP2720696B1 (fr) Combinaison de panobinostat et de ruxolitinib dans le traitement du cancer tel qu'un néoplasme myéloprolifératif
KR102496146B1 (ko) 노화 세포를 사멸시키고 노화 관련 질환 및 장애를 치료하기 위한 방법 및 조성물
Hussaini et al. Therapeutic drug monitoring of voriconazole and posaconazole
JP6957650B2 (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１−［４−ブロモ−５−［１−エチル−７−（メチルアミノ）−２−オキソ−１，２−ジヒドロ−１，６−ナフチリジン−３−イル］−２−フルオロフェニル］−３−フェニルウレアおよびアナログの使用
EP3630125A2 (fr) Composés sénolytiques
RU2671488C2 (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
EP2968379B1 (fr) Promédicaments de l'étoposide pour l'utilisation dans le ciblage de cellules souches cancéreuses
Reddy et al. Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
KR20200035292A (ko) 혈액 암 치료에 사용하기 위한 dhodh 억제제
CN113194752A (zh) Pi3k相关疾病或病症的组合疗法
JP2017521396A (ja) 癌のための併用療法
JP6860949B2 (ja) 癌の処置方法
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
Carlo-Stella et al. A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: Results from the European study
US20220072003A1 (en) Organic compounds
US9642897B2 (en) Treatment of bone diseases
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
CN113164415A (zh) 依拉司群和阿贝西利在患乳腺癌女性中的联合应用
JP2022524047A (ja) 効力を判定するための方法
JP2005526086A (ja) 癌の治療用のｃｄｋ阻害剤と５−ｆｕの組合せ